Subjects with High Risk Invasive Urothelial Carcinoma research hub

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma

This study looks at a medicine called nivolumab for adults who have had surgery for high-risk bladder or urinary tract cancer. Researchers want to find out if taking this treatment after surgery helps stop the cancer from returning and helps people live longer compared with a dummy treatment.